

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

**PASSWORD:**

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS		Welcome to STN International	
1		Web Page for STN Seminar Schedule - N. America	
2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present	
3	NOV 26	MARPAT enhanced with FSORT command	
4	NOV 26	CHEMSAFe now available on STN Easy	
5	NOV 26	Two new SET commands increase convenience of STN searching	
6	DEC 01	ChemPort single article sales feature unavailable	
7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families	
8	DEC 17	Fifty-one pharmaceutical ingredients added to PS	
9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo	
10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data	
11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE	
12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING	
13	FEB 06	Patent sequence location (PSL) data added to USGENE	
14	FEB 10	COMPENDEX reloaded and enhanced	
15	FEB 11	WTEXTILES reloaded and enhanced	
16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art	
17	FEB 19	Increase the precision of your patent queries -- use terms from the IFC Thesaurus, Version 2009.01	
18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2	
19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms	
20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms	
21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters	
22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB	
23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats	
24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants	
25	MAR 11	ESBIOBASE reloaded and enhanced	
26	MAR 20	CAS databases on STN enhanced with new super role	

NEWS 27 MAR 23 for nanomaterial substances  
CA/CAplus enhanced with more than 250,000 patent equivalents from China  
NEWS 28 MAR 30 IMPATENTS reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

EELE 'HOME' ENTERED AT 14:33:08 ON 30 MAR 2009

FILE 'REGISTRY' ENTERED AT 14:33:16 ON 30 MAR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2  
DICTIONARY FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2

New CAS Information Use Policies - enter HELP.USACETERMS for details


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.ccs.org/support/stndgen/stndoc/properties.html>

=> Uploading C:\Program Files\STNEXP\Queries\10572778.str



chain nodes :

10 11 12 13

ring nodes :

1 2 3 4 5 6 7 8 9 14

chain bonds :

9-10 10-11 11-12 11-13 11-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

5-7 7-8 9-10 10-11 11-12 11-13 11-14

exact bonds :

6-9 8-9

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
 11:CLASS 12:CLASS 13:CLASS 14:Atom

Generic attributes :

10:

Number of Carbon Atoms : less than 7


Type of Ring System : Monocyclic

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

-> file caplus  
COST IN U.S. DOLLARS  
SINCE FILE  
ENTRY  
SESSION  
0.96 1.18  
FULL ESTIMATED COST

FILE 'CPLUS' ENTERED AT 14:34:11 ON 30 MAR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Mar 2009 VOL 150 ISS 14  
FILE LAST UPDATED: 29 Mar 2009 (20090329/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at: [www.cas.org/casinfo](http://www.cas.org/casinfo)

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 11 SSS full
      REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.
```

FULL SEARCH INITIATED 14:34:15 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 118058 TO ITERATE

100.0% PROCESSED 118058 ITERATIONS  
SEARCH TIME: 00.00.04

180 ANSWERS

L2 180 SEA SSS FUL L1

L3 7 L2

=> d ibib abs hitstr 1-  
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2009:140234 CAPLUS Full-text  
DOCUMENT NUMBER: 150:199381  
TITLE: A new combination of (a) an  
α-4-β-2-neuronal nicotinic agonist and (b)  
a glycogen synthase kinase 3 (GSK3) inhibitor  
INVENTOR(S): Basun, Hans; Cox, Graham; Nordgren, Ingrid; Bencherif,  
Merouane  
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; Targacept, Inc.  
SOURCE: PCT Int. Appl., 48pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017455	A1	20090205	WO 2008-SE50898	20080729
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2007-952690P	P 20070730

AB The present invention related to a combination of (a) a α4β2-neuronal  
nicotinic agonist and (b) a GSK3 inhibitor. The invention further relates to  
pharmaceutical compns. comprising said combination and to methods of treating  
CNS disorders in mammals by administrating said combination. The invention  
further relates to a kit comprising the combination and use of said kits in  
treatment of CNS disorders such as dementia and/or Alzheimer's Disease.


IT 698345-96-9 733737-00-3

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical  
process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);  
USES (Uses)

(combination of an  $\alpha$ -4- $\beta$ -2-neuronal nicotinic agonist and a glycogen synthase kinase 3 (GSK3) inhibitor for dementia therapy)


RN 698345-96-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 733737-00-3 CAPLUS

CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:139703 CAPLUS Full-text

DOCUMENT NUMBER: 150:222265

TITLE: New therapeutic combination of an antipsychotic and a glycogen synthase kinase 3 (GSK3) inhibitor 958

INVENTOR(S): Basun, Hans; Cox, Graham; Nordgren, Ingrid

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.

SOURCE: PCT Int. Appl., 54pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017453	A1	20090205	WO 2008-SE50896	20080729
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,				

TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2007-952641P P 20070730

AB The present invention relates to a combination of (a) an antipsychotic and (b) a GSK3 inhibitor. The invention further relates to pharmaceutical compns. comprising said combination and to methods of treating psychiatric disorders; particularly, cognitive impairment disorders in psychotic disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of psychiatric disorders; particularly, cognitive impairment disorders in psychotic disorders.


IT 698345-96-9, 2-Hydroxy-3-[5-(4-methylpiperazin-1-yl)sulfonylpyridin-2-yl]-1H-indole-5-carbonitrile 733737-00-3

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(therapeutic combination of an antipsychotic and a glycogen synthase kinase 3 (GSK3) inhibitor 958)


RN 698345-96-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 733737-00-3 CAPLUS

CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2009:138859 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 150:222260

TITLE: New therapeutic combination of a glycogen synthase kinase-3 (GSK3) inhibitor and an  $\alpha$ 7-nicotinic agonist

INVENTOR(S): Basun, Hans; Cox, Graham; Nordgren, Ingrid

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.

SOURCE: PCT Int. Appl., 59pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009017454	A1	20090205	WO 2008-SE50897	20080729

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GM, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-952651P P 20070730  
 AB The present invention related to a combination of (a) a GSK3 inhibitor and (b) an  $\alpha$ 7- nicotinic agonist. The invention further relates to pharmaceutical compns. comprising said combination and to methods of treating CNS disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kits in treatment of CNS disorders such as dementia and/or Alzheimer's Disease.


IT 698345-96-9 733737-00-3

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);  
 USES (Uses)

(combination of a glycogen synthase kinase-3 (GSK3) inhibitor and an  $\alpha$ 7-nicotinic agonist for dementia therapy)


RN 698345-96-9 CAPLUS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 733737-00-3 CAPLUS


CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 7 CAPIUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2005:283287 CAPIUS Full-text  
DOCUMENT NUMBER: 142:336240  
TITLE: Preparation of heterocyclic-substituted indoles as  
inhibitors of GSK3β  
INVENTOR(S): Berg, Stefan; Hellberg, Sven  
PATENT ASSIGNEE(S): AstraZeneca Ab, Swed.  
SOURCE: PCT Int. Appl., 120 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027823	A2	20050331	WO 2004-SE1363	20040921
WO 2005027823	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GB, GM, HR, HD, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004273771	A1	20050331	AU 2004-273771	20040921
AU 2004273771	B2	20081106		
CA 2538381	A1	20050331	CA 2004-2538381	20040921
EP 1667990	A2	20060614	EP 2004-775465	20040921
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004014632	A	20061107	BR 2004-14632	20040921
CN 1886397	A	20061227	CN 2004-80034700	20040921
JP 2007506734	T	20070322	JP 2006-527944	20040921
IN 2006DN01198	A	20070803	IN 2006-DN1198	20060307
US 20080275041	A1	20081106	US 2006-572778	20060321
MX 2006003195	A	20060623	MX 2006-3195	20060322
PRIORITY AFFLN. INFO.:		SE 2003-2546	A 20030924	
		AU 2003-216026	A3 20030328	
		WO 2004-SE1363	W 20040921	
OTHER SOURCE(S):	CASREACT 142:336240; MARPAT 142:336240			
GI				




AB Title compds. I [P = 5-6-membered heteroarom. ring; R1 = H; R2 = alkyl, CN, halo, etc.; R3 = alkyl, CN, NO<sub>2</sub>, carboxy, etc.; m, n = 0-4] and derivs. are prepared. For instance, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl]-1H-indole-6-carbonitrile is prepared by the reaction of 2-oxoindoline-6-carbonitrile and 1-[(6-chloro-1-oxidopyridin-3-yl)carbonyl]-4-methylpiperazine (preparation given). K<sub>i</sub> of selected compds. of the invention was 20  $\mu$ M for GSK3 $\beta$ . I are useful for the treatment of, e.g., Alzheimer's Disease.

IT 698345-96-9P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of heterocyclic-substituted indoles as inhibitors of GSK3 $\beta$ )

RN 698345-96-9 CAPLOS

CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)




IT 848472-62-0P, 2-Hydroxy-3-[5-(piperazine-1-sulfonyl)pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-64-0P,  
 3-[5-[(4-[2-(Dipropylamino)ethyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride 848472-66-2P,  
 3-[5-[(4-[2-(Dipropylamino)ethyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile 848472-68-4P,  
 2-Hydroxy-3-[5-[(4-[2-(morpholin-4-yl)ethyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride  
 848472-70-8P, 2-Hydroxy-3-[5-[(4-[2-(morpholin-4-yl)ethyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile  
 848472-72-0P, 2-Hydroxy-3-[5-[(4-[2-(pyrrolidin-1-yl)ethyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile  
 hydrochloride 848472-74-2P,  
 2-Hydroxy-3-[5-[(4-[2-(pyrrolidin-1-yl)ethyl)piperazin-1-yl]sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile 848472-76-4P,  
 2-Hydroxy-3-[5-[(4-(2-methoxyethyl)piperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 848472-78-6P,  
 2-Hydroxy-3-[5-[(4-(2-methoxyethyl)piperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile 848472-80-0P,  
 2-Hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methylpiperazin-1-

yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848472-82-2P, 2-Hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-33-6P, 2-Hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-35-8P, 2-Hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-39-2P, 2-Hydroxy-N-(4-methoxyphenyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-41-6P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-3-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-43-8P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-4-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-45-0P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(pyridin-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-58-5P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-sulfonamide hydrochloride 848473-61-0P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-63-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carboxamide hydrochloride 848473-64-3P, 3-[5-[(4-[2-(Dimethylamino)ethyl]piperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride 848473-68-7P, 2-Hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-69-8P, 2-Hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848473-70-1P, N-Benzyl-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-71-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-propyl-1H-indole-5-carboxamide hydrochloride 848473-72-3P, 2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-73-4P, N-[2-(Dimethylamino)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-77-8P, 6-Bromo-2-hydroxy-N-methyl-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-78-9P, 6-Bromo-2-hydroxy-N-isopropyl-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-79-0P, 6-Bromo-2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-80-3P, 6-Bromo-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[(tetrahydrofuran-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848473-81-4P, 6-Bromo-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(pyrrolidin-1-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848473-82-5P, N-[3-(Dimethylamino)propyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-83-6P, 2-Hydroxy-N-(2-methoxyethyl)-3-[5-[(morpholin-4-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848473-84-7P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-pyridin-3-yl-1H-indole-5-carboxamide hydrochloride 848473-85-8P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-pyridin-3-yl-1H-indole-5-carboxamide 848473-86-9P, 2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-

yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride  
 848473-87-0P, 2-Hydroxy-N-(2-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide  
 848473-88-1P, 2-Hydroxy-N-(3-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide  
 hydrochloride 848473-89-2P,  
 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-indole-5-carboxamide hydrochloride  
 848473-90-5P, 2-Hydroxy-N-(4-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide  
 hydrochloride 848473-91-6P,  
 2-Hydroxy-N-(4-methoxybenzyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide 848474-01-1P,  
 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylic acid hydrochloride 848474-02-2P,  
 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-indole-5-carboxamide hydrochloride  
 848474-03-3P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[{(thiophene-2-yl)methyl]-1H-indole-5-carboxamide hydrochloride 848474-04-4P,  
 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(2-oximidazolidin-1-yl)ethyl]-1H-indole-5-carboxamide hydrochloride  
 848474-05-5P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(thiophene-2-yl)ethyl]-1H-indole-5-carboxamide hydrochloride 848474-06-6P,  
 N-[2-(Acetylamino)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride  
 848474-07-7P, N-(2-Cyanoethyl)-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride  
 848474-08-8P, N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-09-9P,  
 N-(Cyanomethyl)-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride 848474-10-2P,  
 2-Hydroxy-3-[5-(4-methylpiperazinesulfon-1-yl)pyridin-2-yl]-1H-indole-5-carboxylic acid N-[carbamoyl)methyl]amide hydrochloride  
 848474-11-3P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-[2-(methylsulfonyl)ethyl]-1H-indole-5-carboxamide hydrochloride 848567-90-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of heterocyclic-substituted indoles as inhibitors of GSK3 $\beta$ )

RN 848472-62-8 CAPLUS


CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-(1-piperazinylsulfonyl)-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-64-0 CAPLUS


CN 1H-Indole-6-carbonitrile, 3-[5-[(4-[2-(dipropylamino)ethyl]-1-piperazinyl)sulfonyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 848472-66-2 CAPLUS

CN 1H-Indole-6-carbonitrile, 3-[5-[(4-[2-(dipropylamino)ethyl]-1-piperazinyl)sulfonyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



RN 848472-68-4 CAPLUS


CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-[2-(4-morpholinyl)ethyl]-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 848472-70-8 CAPLUS

CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-[2-(4-morpholinyl)ethyl]-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848472-72-0 CAPLUS


CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 848472-74-2 CAPLUS

CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-[2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848472-76-4 CAPLUS


CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[[4-(2-methoxyethyl)-1-piperazinyl]sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 848472-78-6 CAPLUS

CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-(2-methoxyethyl)-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848472-80-0 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 848472-82-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(3-methoxypropyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848473-33-6 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 848473-35-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848473-39-2 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(4-methoxyphenyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 848473-41-6 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(3-pyridinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 848473-43-8 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(4-pyridinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)




RN 848473-45-0 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(2-pyridinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 848473-58-5 CAPLUS  
CN 1H-Indole-5-sulfonamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 848473-61-0 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-63-2 CAPLUS


CN 1H-Indole-6-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-64-3 CAPLUS


CN 1H-Indole-6-carbonitrile, 3-[5-[[4-[2-(dimethylamino)ethyl]piperazinyl]sulfonyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 848473-68-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848473-69-8 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[2-(1H-imidazol-5-yl)ethyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 848473-70-1 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 848473-71-2 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-72-3 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-73-4 CAPLUS


CN 1H-Indole-5-carboxamide, N-[2-(dimethylamino)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-77-8 CAPLUS

CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-methyl-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848473-78-9 CAPLUS

CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-(1-methylethyl)-3-[5-[(4-


methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-79-0 CAPLUS


CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-N-[(2-methoxyethyl)-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-80-3 CAPLUS


CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[(tetrahydro-2-furanyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-81-4 CAPLUS


CN 1H-Indole-5-carboxamide, 6-bromo-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-82-5 CAPLUS


CN 1H-Indole-5-carboxamide, N-[3-(dimethylamino)propyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-83-6 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-(2-methoxyethyl)-3-[5-(4-morpholinylsulfonyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 848473-84-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-3-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 848473-85-0 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 848473-86-9 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848473-87-0 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(2-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



RN 848473-88-1 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(3-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 848473-89-2 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848473-90-5 CAPLUS


CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(4-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848473-91-6 CAPLUS

CN 1H-Indole-5-carboxamide, 2-hydroxy-N-[(4-methoxyphenyl)methyl]-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)




RN 848474-01-1 CAPLUS  
CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 848474-02-2 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848474-03-3 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-(2-thienylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 848474-04-4 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 848474-05-5 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(2-thienyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848474-06-6 CAPLUS  
CN 1H-Indole-5-carboxamide, N-[2-(acetylamino)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848474-07-7 CAPLUS  
CN 1H-Indole-5-carboxamide, N-(2-cyanoethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848474-08-8 CAPLUS  
CN 1H-Indole-5-carboxamide, N-[2-(aminosulfonyl)ethyl]-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848474-09-9 CAPLUS  
CN 1H-Indole-5-carboxamide, N-(cyanomethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 848474-10-2 CAPLUS  
CN 1H-Indole-5-carboxamide, N-(2-amino-2-oxoethyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)




● HCl

RN 848474-11-3 CAPLUS  
CN 1H-Indole-5-carboxamide, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 848567-90-0 CAPLUS  
CN 1H-Indole-5-carboxamide, N-(3-amino-3-oxopropyl)-2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)



IT 848473-37-0, Methyl 2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylate  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of heterocyclic-substituted indoles as inhibitors of GSK3 $\beta$ )  
 RN 848473-37-0 CAPLUS  
 CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, methyl ester (CA INDEX NAME)




IT 848472-48-0P, Methyl 2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylate hydrochloride  
 848472-50-4P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxylic acid  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of heterocyclic-substituted indoles as inhibitors of GSK3 $\beta$ )  
 RN 848472-48-0 CAPLUS  
 CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 848472-50-4 CAPLUS  
 CN 1H-Indole-5-carboxylic acid, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]- (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 7 CAPIUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:796689 CAPIUS [Full-text](#)  
 DOCUMENT NUMBER: 139:323431  
 TITLE: Preparation of heterocyclic 1-substituted 2-oxindoles and 2,3-dihydro-1H-indol-2-ols as glycogen synthase kinase-3 inhibitors  
 INVENTOR(S): Berg, Stefan; Hellberg, Sven; Nyloef, Martin; Xue, Yafeng  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.  
 SOURCE: PCT Int. Appl., 114 pp.  
 CODEN: FIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082853	A1	20031009	WO 2003-SE508	20030328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2476343	A1	20031009	CA 2003-2476343	20030328
AU 2003216026	A1	20031013	AU 2003-216026	20030328
AU 2003216026	B2	20081211		
EP 1492785	A1	20050105	EP 2003-745498	20030328
EP 1492785	B1	20081203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008196	A	20050111	BR 2003-8196	20030328
CN 1642938	A	20050720	CN 2003-807389	20030328
JP 200526814	T	20050908	JP 2003-580319	20030328
JP 3989444	B2	20071010		
CN 1923812	A	20070307	CN 2006-10153714	20030328
NZ 534664	A	20070629	NZ 2003-534664	20030328
EP 1961748	A2	20080827	EP 2008-157461	20030328
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK				
RU 2338742	C2	20081120	RU 2004-125146	20030328
AT 416171	T	20081215	AT 2003-745498	20030328

MX 2004009163	A	20041207	MX 2004-9163	20040921
ZA 2004007665	A	20050829	ZA 2004-7665	20040922
US 20050153987	A1	20050714	US 2004-509268	20040927
US 7399780	B2	20080715		
NO 2004004432	A	20041019	NO 2004-4432	20041019
JP 2007224051	A	20070906	JP 2007-155810	20070613
PRIORITY APPLN. INFO.:			SE 2002-979	A 20020328
			CN 2003-807389	A3 20030328
			EP 2003-745498	A3 20030328
			JP 2003-580319	A3 20030328
			WO 2003-SE508	W 20030328

OTHER SOURCE (S) : MARPAT 139:323431  
GI




AB Title compds. I and II [wherein P = 5- or 6-membered heterocarom. ring; R1 = H; R2 and R3 = independently halo, NO<sub>2</sub>, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, CHO, COR4, CO<sub>2</sub>R4, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, OCH<sub>2</sub>F, OCHF<sub>2</sub>, OCF<sub>3</sub>, OC<sub>2</sub>R4, NR4OR5, NR4CO<sub>2</sub>R5, SO<sub>3</sub>R4, XR6; R4 = H, alkyl, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, alkyl-NR14R15, or (un)substituted heterocycl; R5 = H or (un)substituted alkyl, alkenyl, alkynyl, alkylcycloalkyl, alkyl(hetero)aryl, or alkyl-NR14R15; or NR4R5 = (un)substituted heterocycl; R6 = (un)substituted Ph or heterocycl; R7, R9, and R12 = independently H or alkyl; R8, R10, R11, and R13 = independently alkyl; R14 and R15 = independently H or alkyl(cycloalkyl); or NR14R15 = (un)substituted heterocycl; X = direct bond, O, COR7R8, SO<sub>2</sub>NR9R10, or NR12R13; OCOR4 (un)substituted alkyl or alkoxy; m = 0-4; n = 0-4; and their pharmaceutically acceptable salts thereof] were prepared as glycogen synthase kinase-3 (GSK3) inhibitors. For example, reduction of 5-cyanoindole with NaH in DMF, followed by coupling with 2-chloro-N-[2-(dimethylamino)ethyl]isonicotinamide in DMF provided the title indolol III (5%). In ATP competition assays, compds. of the invention inhibited recombinant human GSK3 with IC<sub>50</sub> values in the range of about 0.001 nM to about 10,000 nM (no specific values given). Thus, I, II, and their pharmaceutical formulations are useful for the treatment of a variety of neurodegenerative and dementia related diseases, including Alzheimer's disease (no data).  
IT 612488-22-9P, 3-[3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(GSK3 inhibitor; preparation of (heterocycl)oxindoles and indolols as GSK3 inhibitors for treatment of neurodegenerative diseases, dementia, and related disorders)

RN 612488-22-9 CAPLUS

CN 1H-Indol-2-ol, 3-[3-bromo-5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-nitro- (CA INDEX NAME)




IT 612488-78-2P, 2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride  
612488-00-3P, 3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-01-4P,  
6-Chloro-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indol-2-ol hydrochloride 612488-14-9P,  
3-[5-[(4-Benzylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile hydrochloride 612488-15-0P,  
2-Hydroxy-3-[5-[(4-(3-methylbutyl)piperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612488-16-1P,  
2-Hydroxy-3-[5-[(4-isopropylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile hydrochloride 612488-17-2P,  
3-[5-[(4-Ethylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1H-indole-5-carbonitrile hydrochloride 612488-21-8P,  
3-[3-Bromo-5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-nitro-1H-indol-2-ol hydrochloride 612488-24-1P,  
2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride 612488-44-5P,  
2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-45-6P,  
2-Hydroxy-3-[5-[(morpholin-4-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile 612488-46-7P,  
3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(2-methylthiazol-4-yl)-1H-indol-2-ol hydrochloride 612488-48-9P,  
3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(thiazol-4-yl)-1H-indol-2-ol fumarate 612488-49-0P,  
3-[5-[(4-Methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-5-(oxazol-5-yl)-1H-indol-2-ol 612488-57-0P,  
2-Hydroxy-3-[5-[(4-methyl-1,4-diazepan-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carbonitrile fumarate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(GSK3 inhibitor; preparation of (heterocycl)oxindoles and indolols as GSK3 inhibitors for treatment of neurodegenerative diseases, dementia, and related disorders)

RN 612487-78-2 CAPLUS  
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 612488-00-3 CAPLUS  
CN 1H-Indol-2-ol, 3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 612488-01-4 CAPLUS  
CN 1H-Indol-2-ol, 6-chloro-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 612488-14-9 CAPLUS  
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-(phenylmethyl)-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 612488-15-0 CAPLUS


CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-(3-methylbutyl)-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 612488-16-1 CAPLUS


CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-[(4-(1-methylethyl)-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 612488-17-2 CAPLUS

CN 1H-Indole-5-carbonitrile, 3-[5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-2-hydroxy-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 612488-21-8 CAPLUS  
CN 1H-Indol-2-ol, 3-[3-bromo-5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-nitro-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 612488-24-1 CAPLUS  
CN 1H-Indole-6-carbonitrile, 2-hydroxy-3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl


RN 612488-44-5 CAPLUS  
CN 1H-Indole-5-carbonitrile, 3-[5-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)sulfonyl]-2-pyridinyl]-2-hydroxy- (CA INDEX NAME)



RN 612488-45-6 CAPLUS  
CN 1H-Indole-5-carbonitrile, 2-hydroxy-3-[5-(4-morpholinylsulfonyl)-2-pyridinyl]- (CA INDEX NAME)



RN 612488-46-7 CAPLUS  
CN 1H-Indol-2-ol, 3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-(2-methyl-4-thiazolyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 612488-48-9 CAPLUS  
CN Piperazine, 1-[(6-[2-hydroxy-5-(4-thiazolyl)-1H-indol-3-yl]-3-pyridinyl)sulfonyl]-4-methyl-, (2E)-2-butenedicarboxylate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-47-8  
CMF C21 H21 N5 O3 S2




CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.




RN 612488-49-0 CAPLUS  
CN 1H-Indol-2-ol, 3-[5-[(4-methyl-1-piperazinyl)sulfonyl]-2-pyridinyl]-5-(5-oxazolyl)- (CA INDEX NAME)



RN 612488-57-0 CAPLUS  
CN 1H-1,4-Diazepine, 1-[[6-(5-cyano-2-hydroxy-1H-indol-3-yl)-3-pyridinyl]sulfonyl]hexahydro-4-methyl-, (2E)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 612488-44-5  
CMF C20 H21 N5 O3 S



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 20021312012 CAPLUS Full-text  
 DOCUMENT NUMBER: 136:340996  
 TITLE: Preparation of sulfamides as metalloprotease inhibitors  
 INVENTOR(S): Broka, Chris Allen; Campbell, Jeffrey Allen;  
 Castelhano, Arlindo Lucas; Chen, Jian Jeffrey;  
 Hendricks, Robert Than; Melnick, Michael Joseph;  
 Walker, Keith Adrian Murray  
 PATENT ASSIGNEE (S): Syntex (U.S.A.) LLC, USA; Agouron Pharmaceuticals, Inc.  
 SOURCE: U.S., 47 pp., Cont.-in-part of U.S. 6,143,744.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6376506	B1	20020423	US 1999-469677	19991222
CA 2278694	A1	19980730	CA 1998-2278694	19980114
CA 2278694	C	20060926		
AU 9866140	A	19980818	AU 1998-66140	19980114
AU 730127	B2	20010222		
EP 958287	A1	19991124	EP 1998-907943	19980114
EP 958287	B1	20020911		
EP 958287	B2	20080409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK				
BR 9807508	A	20000321	BR 1998-7508	19980114
NZ 336625	A	20010427	NZ 1998-336625	19980114
HU 2000000941	A2	20010428	HU 2000-941	19980114
HU 2000000941	A3	20020628		
JP 2001523222	T	20011120	JP 1998-531537	19980114
JP 3563411	B2	20040908		
AT 223909	T	20020915	AT 1998-907943	19980114
ZA 9800376	A	19980723	ZA 1998-376	19980116
US 5998412	A	19991207	US 1998-9951	19980121
NO 9903587	A	19990922	NO 1999-3587	19990722
NO 313635	B1	20021104		
MX 9906822	A	20000131	MX 1999-6822	19990722
US 6130220	A	20001010	US 1999-369677	19990805
US 6143744	A	20001107	US 1999-369501	19990805
PRIORITY APPLN. INFO.:				
		US 1997-36714P	P	19970123
		US 1997-62209P	P	19971016
		US 1998-9951	A3	19980121
		US 1999-369501	A2	19990805
		WO 1998-EP180	W	19980114

OTHER SOURCE (S): MARPAT 136:340996

AB Sulfamides  $RCOCR1R2NR3SO2NR4R5$  [R = OH, NHOB or N/O-alkyl or -aryl derivs.; R1, R2, R3 = H, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, (hetero)aryl, acylalkyl, etc.; R1R2C may be a (hetero)carbocycle or R3 together with R1 or R2 form a heterocycloamino group; R4, R5 = H, alkyl, heteroalkyl, cycloalkyl, cycloalkylalkyl, aryl, (hetero)aralkyl or -aralkenyl; R4R5N may be a heterocycloamino group or R4 or R5 together with R3 forms an alkylene group (with provisos)], as individual isomers or mixts. of isomers, or their pharmaceutically-acceptable salts or prodrugs were prepared as inhibitors of metalloproteases. Thus, 2-(R)-[(1,2,3,4-tetrahydro- $\beta$ -carboline-2-sulfonyl)amino]propionic acid (claimed compound) was prepared by treating D-alanine Me ester hydrochloride with chlorosulfonyl isocyanate/2-chloroethanol, reaction of the oxazolidone formed with 1,2,3,4-tetrahydro- $\beta$ -carboline, and saponification. Metalloprotease and TNF- $\alpha$  inhibitory test data are tabulated.

IT 1100982-59-9


RL: PRPH (Prophetic)

(Preparation of sulfamides as metalloprotease inhibitors)

RN 1100982-59-9 CAPLUS

CN 2-Piperazinecarboxamide, 4-(cyclopropylmethyl)-1-[(4-[5-fluoro-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 210916-51-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of sulfamides as metalloprotease inhibitors)

RN 210916-51-1 CAPLUS

CN 1,3-Piperazinedicarboxamide, N1,N1-dimethyl-N3-(phenylmethoxy)-4-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 210915-38-1P 210915-40-5P 210915-57-4P  
 210915-59-6P 210915-60-9P 210915-61-0P  
 210915-69-8P 210915-71-2P 210915-72-3P  
 210915-76-7P 210915-78-9P 210915-83-6P  
 210915-86-9P 210915-87-0P 210915-88-1P  
 210915-89-2P 210915-90-5P 210915-91-6P  
 210915-92-7P 210915-93-8P 210915-94-9P  
 210915-95-0P 210915-96-1P 210916-01-1P  
 210916-05-5P 210916-08-8P 210916-09-9P  
 210916-14-6P 210916-16-8P 210916-17-9P  
 210916-46-4P 210916-47-5P 210916-48-6P  
 210916-49-7P 210916-50-0P 210916-52-2P  
 210916-53-3P 210916-54-4P 210916-55-5P  
 210916-60-2P 210916-61-3P 210916-97-5P  
 210917-01-4P 210917-04-7P 416846-37-2P  
 416846-38-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfamides as metalloprotease inhibitors)


RN 210915-38-1 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210915-40-5 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-(6-chloro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210915-57-4 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-(5-chloro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210915-59-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-60-9 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[(4-(6-chloro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 210915-61-0 CAPLUS  
CN 2-Piperazinecarboxamide, 4-acetyl-N-hydroxy-1-[(4-(6-methyl-1H-indol-3-yl)-1-piperidinylsulfonyl)- (CA INDEX NAME)




RN 210915-69-8 CAPLUS  
CN 2-Piperazinecarboxamide, 1-[(4-(4-chloro-1H-indol-3-yl)-1-piperidinylsulfonyl)-N-hydroxy- (CA INDEX NAME)




RN 210915-71-2 CAPLUS  
CN 2-Piperazinecarboxamide, 1-[(4-(6-fluoro-1H-indol-3-yl)-1-piperidinylsulfonyl)-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210915-72-3 CAPLUS  
CN 2-Piperazinecarboxamide, N-hydroxy-1-[(4-(5-methoxy-1H-indol-3-yl)-1-piperidinylsulfonyl)- (CA INDEX NAME)



RN 210915-76-7 CAPLUS


CN 2-Piperidinecarboxamide, N-hydroxy-1-[(4-(5-hydroxy-1H-indol-3-yl)-1-piperidinyl)sulfonyl]- (CA INDEX NAME)



RN 210915-78-9 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 210915-83-6 CAPLUS

CN 2-Piperidinecarboxamide, N-hydroxy-1-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 210915-86-9 CAPLUS  
 CN 1,3-Piperazinedicarboxamide, N1-(1,1-dimethylethyl)-4-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N3-hydroxy- (CA INDEX NAME)



RN 210915-87-0 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[(4-[4,5,6,7-tetrafluoro-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-88-1 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-89-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-3-[(hydroxyamino)carbonyl]-, methyl ester (CA INDEX NAME)



RN 210915-90-5 CAPLUS


CN 2-Piperazinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-4-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (CA INDEX NAME)



RN 210915-91-6 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-[5-(acetylamino)-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-92-7 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(2S)-2-amino-3-methyl-1-oxobutyl]-1-[(4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-93-8 CAPLUS

CN 1,3-Piperazinedicarboxamide, N3-hydroxy-N1,N1-dimethyl-4-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-94-9 CAPLUS


CN 2-Piperazinecarboxamide, 4-(cyclopropylmethyl)-1-[(4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210915-95-0 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(dimethylamino)sulfonyl]-1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210915-96-1 CAPLUS


CN 2-Piperazinecarboxamide, 4-[(bis(dimethylamino)phosphoryl)-1-[(4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210916-01-1 CAPLUS

CN 1,3-Piperazinedicarboxamide, 4-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N1-(1,1-dimethylethyl)-N3-hydroxy-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-05-5 CAPLUS

CN 2-Piperazinecarboxamide, 1-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-4-(4-morpholinylcarbonyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-08-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-[5-cyano-1-(methylsulfonyl)-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-09-9 CAPLUS

CN 3-Thiomorpholinecarboxamide, 4-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-2,2-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-14-6 CAPLUS


CN 2-Piperazinecarboxamide, 1-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-4-(2-pyrazinylcarbonyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 210916-16-8 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[(4-[6-chloro-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-3-[(hydroxymethyl)carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 210916-17-9 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[(4-[6-fluoro-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-3-

[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 210916-46-4 CAPLUS


CN 2-Piperazinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-4-formyl-N-(phenylmethoxy)- (CA INDEX NAME)



RN 210916-47-5 CAPLUS


CN 2-Piperazinecarboxamide, N-(phenylmethoxy)-1-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210916-48-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-3-[(phenylmethoxy)amino]carbonyl-, methyl ester (CA INDEX NAME)



RN 210916-49-7 CAPLUS


CN 2-Piperazinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-(phenylmethoxy)-4-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (CA INDEX NAME)



RN 210916-50-0 CAPLUS

CN 1,3-Piperazinedicarboxamide, N1-(1,1-dimethylethyl)-N3-(phenylmethoxy)-4-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-52-2 CAPLUS

CN 2-Piperidinecarboxamide, N-hydroxy-N-(4-morpholinylmethyl)-1-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-53-3 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-54-4 CAPLUS

CN 1,3-Piperazinedicarboxamide, 4-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N1,N1-dimethyl-N3-(phenylmethoxy)-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-55-5 CAPLUS


CN 2-Piperidinecarboxamide, 1-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-methoxy-N-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210916-60-2 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-(5-chloro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210916-61-3 CAPLUS


CN 2-Piperidinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210916-97-5 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[(4-(6-chloro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210917-01-4 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[(4-(5-chloro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]- (CA INDEX NAME)



RN 210917-04-7 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[(4-(5-methyl-1H-indol-3-yl)-1-piperidinyl)sulfonyl]- (CA INDEX NAME)



RN 416846-37-2 CAPLUS

CN 2-Piperazinecarboxamide, 1-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-4-[(dimethylamino)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 416846-38-3 CAPLUS

CN 2-Piperazinecarboxamide, 4-(cyclopropylmethyl)-1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 210917-46-7P 210917-47-8P 210917-51-4P

210917-52-5P 210917-53-6P 210917-55-8P

210917-56-9P 210917-57-0P 210917-58-1P

210917-59-2P 210917-68-3P 210917-69-4P


416846-40-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of sulfamides as metalloprotease inhibitors)


RN 210917-46-7 CAPLUS

CN 1,3-Piperazinedicarboxylic acid, 4-[(4-[5-fluoro-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-, 1-(phenylmethyl) ester (CA INDEX NAME)



RN 210917-47-8 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[(4-[5-fluoro-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-3-[(hydroxymino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 210917-51-4 CAPLUS

CN 1,3-Piperazinedicarboxylic acid, 4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinylsulfonyl]-, 1-(1,1-dimethylethyl) ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-52-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[[[(phenylmethoxy)amino]carbonyl]-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinylsulfonyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-53-6 CAPLUS

CN 2-Piperazinecarboxamide, N-(phenylmethoxy)-1-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinylsulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-55-8 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, methyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-56-9 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-57-0 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-58-1 CAPLUS


CN 2-Piperidinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-methyl-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 210917-59-2 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[(4-(5-hydroxy-1H-indol-3-yl)-1-piperidinyl)sulfonyl]- (CA INDEX NAME)



RN 210917-68-3 CAPLUS

CN 2-Piperazinecarboxamide, 1-[(4-[5-cyano-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-69-4 CAPLUS

CN 2-Piperazinecarboxamide, 1-[(4-[5-cyano-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-4-[(dimethylamino)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 416846-40-7 CAPLUS

CN 2-Piperazinecarboxamide, 1-[(4-[5-fluoro-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1998:498326 CAPLUS Full-text  
DOCUMENT NUMBER: 129:148991  
ORIGINAL REFERENCE NO.: 129:30373a,30376a  
TITLE: Preparation of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as metalloproteinase inhibitors  
INVENTOR(S): Broka, Chris Allen; Campbell, Jeffrey Allen; Castelhano, Arlindo Lucas; Chen, Jian Jeffrey; Hendricks, Robert Than; Melnick, Michael Joseph; Walker, Keith Adrian Murray  
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.; Agouron Pharmaceuticals, Inc.  
SOURCE: Ger. Offen., 84 pp.  
CODEN: GWXXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19802350	A1	19980730	DE 1998-19802350	19980122
CA 2278694	A1	19980730	CA 1998-2278694	19980114
CA 2278694	C	20060926		
WO 9832748	A1	19980730	WO 1998-EP180	19980114
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UK, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9866140	A	19980818	AU 1998-66140	19980114
AU 730127	B2	20010222		
EP 958287	A1	19991124	EP 1998-907943	19980114
EP 958287	B1	20020911		
EP 958287	B2	20080409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK				
BR 9807508	A	20000321	BR 1998-7508	19980114
NZ 336625	A	20010427	NZ 1998-336625	19980114
HU 2000000941	A2	20010428	HU 2000-941	19980114
HU 2000000941	A3	20020628		
JP 2001523222	T	20011120	JP 1998-531537	19980114
JP 3563411	B2	20040908		
AT 223909	T	20020915	AT 1998-907943	19980114
CN 1093125	C	20021023	CN 1998-803233	19980114
ES 2183331	T3	20030316	ES 1998-907943	19980114
ZA 9800376	A	19980723	ZA 1998-376	19980116
IN 1998MA00105	A	20050304	IN 1998-MA105	19980116
IT 1298163	B1	19991220	IT 1998-MI91	19980120
FR 2758559	A1	19980724	FR 1998-601	19980121
GB 2321641	A	19980805	GB 1998-1393	19980122
GB 2321641	B	20010401		
ES 2136037	A1	19991101	ES 1998-113	19980122

ES 2136037	B1	20001116	NO 1999-3587	19990722
NO 9903587	A	19990922	US 1997-36714P	P 19970123
NO 313635	B1	20021104	US 1997-62209P	P 19971016
MX 9906822	A	20000131	WO 1998-EP180	W 19980114
PRIORITY APPLN. INFO.:				

OTHER SOURCE (S) : MARPAT 129:148991  
GI




AB R10COCCR1R2NR3SO2NR20R21 [I; R1-R3 = H, (CO-interrupted) alkyl, heterocyclyl(alkyl), (hetero)aryl(alkyl), etc.; R1R2, R1R3, R2R3 = atoms to complete a ring; R10 = NR11OR12; R11,R12 = H or (ar)alkyl; R20,R21 = H, alkyl, (hetero)aryl[alk(en)yl], etc.; NR20R21heterocyclyl] were prepared. Thus, (R)-1-[4-(4-chlorobenzoyl)piperidine-1-sulfonyl]piperidine-2- carboxylic acid was amidated by H2NOCMe3 and the product deprotected to give title compound (R)-II. Data for biol. activity of I were given.


IT 210915-38-1P 210915-40-5P 210915-57-4P  
 210915-59-6P 210915-60-9P 210915-61-0P  
 210915-69-8P 210915-71-2P 210915-72-3P  
 210915-76-7P 210915-78-9P 210915-83-6P  
 210915-86-9P 210915-87-0P 210915-88-1P  
 210915-89-2P 210915-90-5P 210915-91-6P  
 210915-92-7P 210915-93-8P 210915-94-9P  
 210915-95-0P 210915-96-1P 210916-01-1P  
 210916-05-5P 210916-08-8P 210916-09-9P  
 210916-14-6P 210916-16-8P 210916-17-9P  
 210916-46-4P 210916-47-5P 210916-48-6P  
 210916-49-7P 210916-50-0P 210916-51-1P  
 210916-52-2P 210916-53-3P 210916-54-4P  
 210916-55-5P 210916-60-2P 210916-61-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as metalloproteinase inhibitors)


RN 210915-38-1 CAPLUS  
 CN 2-Piperidinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210915-40-5 CAPLUS  
 CN 2-Piperidinecarboxamide, 1-[(4-(6-chloro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210915-57-4 CAPLUS  
 CN 2-Piperidinecarboxamide, 1-[(4-(5-chloro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210915-59-6 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-60-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-(6-chloro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210915-61-0 CAPLUS

CN 2-Piperazinecarboxamide, 4-acetyl-N-hydroxy-1-[(4-(6-methyl-1H-indol-3-yl)-1-piperidinyl)sulfonyl]- (CA INDEX NAME)



RN 210915-69-8 CAPLUS


CN 2-Piperidinecarboxamide, 1-[(4-(4-chloro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210915-71-2 CAPLUS


CN 2-Piperidinecarboxamide, 1-[(4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210915-72-3 CAPLUS

CN 2-Piperidinecarboxamide, N-hydroxy-1-[(4-(5-methoxy-1H-indol-3-yl)-1-piperidinyl)sulfonyl]- (CA INDEX NAME)



RN 210915-76-7 CAPLUS


CN 2-Piperidinecarboxamide, N-hydroxy-1-[(4-(5-hydroxy-1H-indol-3-yl)-1-piperidinyl)sulfonyl]- (CA INDEX NAME)



RN 210915-78-9 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-83-6 CAPLUS


CN 2-Piperidinecarboxamide, N-hydroxy-1-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210915-86-9 CAPLUS

CN 1,3-Piperazinedicarboxamide, N1-(1,1-dimethylethyl)-4-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N3-hydroxy- (CA INDEX NAME)




RN 210915-87-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-1H-indol-3-yl-phenylmethyl ester (CA INDEX NAME)




RN 210915-88-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, phenylmethyl ester  
(CA INDEX NAME)




RN 210915-89-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-[(hydroxyamino)carbonyl]-, methyl ester (CA INDEX NAME)



RN 210915-90-5 CAPLUS


CN 2-Piperazinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-hydroxy-4-[(tetrahydro-2H-pyran-4-yl)carbonyl]-  
(CA INDEX NAME)



RN 210915-91-6 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-[(acetylamino)-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-92-7 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(2S)-2-amino-3-methyl-1-oxobutyl]-1-[(4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-93-8 CAPLUS

CN 1,3-Piperazinedicarboxamide, N3-hydroxy-N1,N1-dimethyl-4-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210915-94-9 CAPLUS


CN 2-Piperazinecarboxamide, 4-(cyclopropylmethyl)-1-[(4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210915-95-0 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(dimethylamino)sulfonyl]-1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210915-96-1 CAPLUS


CN 2-Piperazinecarboxamide, 4-[bis(dimethylamino)phosphinyl]-1-[(4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)



RN 210916-01-1 CAPLUS

CN 1,3-Piperazinedicarboxamide, 4-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N1-(1,1-dimethylethyl)-N3-hydroxy-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-05-5 CAPLUS

CN 2-Piperazinecarboxamide, 1-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-4-(4-morpholinylcarbonyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-08-8 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-[5-cyano-1-(methylsulfonyl)-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-N-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-09-9 CAPLUS

CN 3-Thiomorpholinecarboxamide, 4-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-2,2-dimethyl-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-14-6 CAPLUS


CN 2-Piperazinecarboxamide, 1-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-4-(2-pyrazinylcarbonyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210916-16-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-[(6-chloro-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-3-[(hydroxyamino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 210916-17-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(4-[6-fluoro-1-[(2-(trimethylsilyl)ethylsulfonyl)-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-3-[(hydroxymino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 210916-46-4 CAPLUS


CN 2-Piperazinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-4-formyl-N-(phenylmethoxy)- (CA INDEX NAME)



RN 210916-47-5 CAPLUS


CN 2-Piperidinecarboxamide, N-(phenylmethoxy)-1-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 210916-48-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-3-[(phenylmethoxy)amino]carbonyl]-, methyl ester  
(CA INDEX NAME)



RN 210916-49-7 CAPLUS


CN 2-Piperazinecarboxamide, 1-[[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N-(phenylmethoxy)-4-[(tetrahydro-2H-pyran-4-yl)carbonyl]- (CA INDEX NAME)



RN 210916-50-0 CAPLUS

CN 1,3-Piperazinedicarboxamide, N1-(1,1-dimethylethyl)-N3-(phenylmethoxy)-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (3R)-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 210916-51-1 CAPLUS

CN 1,3-Piperazinedicarboxamide, N1,N1-dimethyl-N3-(phenylmethoxy)-4-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210916-52-2 CAPLUS

CN 2-Piperidinecarboxamide, N-hydroxy-N-(4-morpholinylmethyl)-1-[(4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



BN 210916-53-3 CAPLUS

CN 2-Piperidinocarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-hydroxy-N-methyl-, (2R)- (CA INDEX NAME)


### Absolute stereochemistry.



BN 210916-54-4 CAPIUS

CN 1,3-Piperazinedicarboxamide, 4-[[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-N1,N1-dimethyl-N3-(phenylmethoxy)-, (3R)- (CA INDEX NAME)


### Absolute stereochemistry.




BN 210916-55-5 CAPIUS

CN 2-Piperidin carboxamide, 1-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-methoxy-N-methyl-, (2R)- (CA INDEX NAME)


### Absolute stereochemistry.



RN 210916-60-2 CAPLUS  
CN 2-Piperidinecarboxamide, 1-[(4-(5-chloro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)




RN 210916-61-3 CAPLUS  
CN 2-Piperidinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl)sulfonyl]-N-hydroxy- (CA INDEX NAME)




IT 210916-97-5P 210917-01-4P 210917-04-7P  
210917-46-7P 210917-47-8P 210917-51-4P  
210917-52-5P 210917-53-6P 210917-55-8P  
210917-56-9P 210917-57-0P 210917-58-1P  
210917-59-2P 210917-67-2P 210917-68-3P  
210917-69-4P 210917-70-7P  
RL: RCT (Reactant); SPPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of N-sulfamoylpiperidine-2-hydroxamic acids and analogs as metalloproteinase inhibitors)

RN 210916-97-5 CAPLUS  
CN 2-Piperidinecarboxylic acid, 1-[(4-(6-chloro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 210917-01-4 CAPLUS  
CN 2-Piperidinecarboxylic acid, 1-[(4-(5-chloro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]- (CA INDEX NAME)




RN 210917-04-7 CAPLUS  
CN 2-Piperidinecarboxylic acid, 1-[(4-(5-methyl-1H-indol-3-yl)-1-piperidinyl)sulfonyl]- (CA INDEX NAME)



RN 210917-46-7 CAPLUS  
CN 1,3-Piperazinedicarboxylic acid, 4-[(4-[5-fluoro-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-, 1-(phenylmethyl) ester (CA INDEX NAME)




RN 210917-47-8 CAPLUS  
CN 1-Piperazinedicarboxylic acid, 4-[(4-[5-fluoro-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-3-[(hydroxymino)carbonyl]-, phenylmethyl ester (CA INDEX NAME)



RN 210917-51-4 CAPLUS

CN 1,3-Piperazinedicarboxylic acid, 4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, 1-(1,1-dimethylethyl) ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-52-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[[[(phenylmethoxy)amino]carbonyl]-4-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-53-6 CAPLUS

CN 2-Piperazinecarboxamide, N-(phenylmethoxy)-1-[[4-(4,5,6,7-tetrafluoro-1H-indol-3-yl)-1-piperidinyl]sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-55-8 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, methyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-56-9 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-57-0 CAPLUS

CN 2-Piperidinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-58-1 CAPLUS


CN 2-Piperidinecarboxamide, 1-[(4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-N-methyl-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 210917-59-2 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[(4-(5-hydroxy-1H-indol-3-yl)-1-piperidinyl)sulfonyl]- (CA INDEX NAME)



RN 210917-67-2 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[(4-[5-cyano-1-(methylsulfonyl)-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-68-3 CAPLUS

CN 2-Piperazinecarboxamide, 1-[(4-[5-cyano-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-69-4 CAPLUS

CN 2-Piperazinecarboxamide, 1-[(4-[5-cyano-1-[(2-(trimethylsilyl)ethyl)sulfonyl]-1H-indol-3-yl]-1-piperidinyl)sulfonyl]-4-[(dimethylamino)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 210917-70-7 CAPLUS

CN 2-Piperazinecarboxamide, 1-[(4-(5-cyano-1H-indol-3-yl)-1-piperidinyl)sulfonyl]-4-[(dimethylamino)sulfonyl]-N-(phenylmethoxy)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



-> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 14:35:01 ON 30 MAR 2009